Get the Stockscreener App
2.93
1.68%
-0.05
After Hours:
2.99
0.06
+2.05%
Adagene Inc Adr stock is traded at $2.93, with a volume of 196.89K.
It is down -1.68% in the last 24 hours and down -23.30% over the past month.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
See More
Previous Close:
$2.98
Open:
$2.96
24h Volume:
196.89K
Relative Volume:
0.71
Market Cap:
$196.73M
Revenue:
$7.69M
Net Income/Loss:
$-17.65M
P/E Ratio:
-7.8279
EPS:
-0.3743
Net Cash Flow:
$-15.72M
1W Performance:
-11.48%
1M Performance:
-23.30%
6M Performance:
-28.01%
1Y Performance:
+45.05%
1-Day Range:
$2.87
$3.185
1-Week Range:
$2.81
$3.35
52-Week Range:
$1.30
$4.85
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
2.93 | 196.73M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Guggenheim | Buy |
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Jan-31-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-25-21 | Initiated | China Renaissance | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Adagene Inc Adr Stock (ADAG) Latest News
Form 4 Adagene Inc. For: 25 September By Investing.com - Investing.com Nigeria
Form 4 Adagene Inc. For: 25 September - Investing.com India
A $3-a-share purchase leaves Adagene (ADAG) finance chief Tam Man Kin holding 12,000 depositary shares. - Stock Titan
Adagene Announces Finance Executive Resignation Effective September 30, 2026 - TipRanks
A finance director’s resignation takes effect Sept. 30 at Adagene (ADAG). - Stock Titan
ADAG Stock Price, Quote & Chart - ChartMill
Adagene (NASDAQ: ADAG) Obtains NMPA IND Approval for ADG138 Phase 1 Trial in Advanced Solid Tumors - Kalkine Media
China approves Adagene’s IND application for ADG138 cancer drug - Investing.com
China greenlights Adagene (NASDAQ: ADAG) cancer drug for first human trial - Stock Titan
Adagene Announces NMPA Clearance of Investigational New - GlobeNewswire
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know - Eastern Progress
Adagene Stock Price Forecast. Should You Buy ADAG? - StockInvest.us
Co- Founder of Adagene Peter P. Luo Buys 30% More Shares - simplywall.st
H.C. Wainwright reiterates Adagene stock rating on milestone payments - Investing.com
Adagene, Third Arc Bio expand partnership with first lead selection - investing.com
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - The Manila Times
Cancer partner will fund new trials in Adagene (ADAG) collaboration - Stock Titan
Adagene Secures Milestone Payments in Exelixis SAFEbody ADC Collaboration - TipRanks
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - Yahoo! Finance Canada
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Barchart.com
Adagene (NASDAQ: ADAG) officer to sell 131K ADS to cover option taxes - Stock Titan
Adagene to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Adagene (NASDAQ: ADAG) officer plans August ADS sell-to-cover - Stock Titan
Adagene (ADAG): WuXi PharmaTech and WuXi AppTec disclose 3.5% beneficial stake - Stock Titan
Adagene Inc. (Nasdaq: ADAG) boosts cash to US$127.9M and updates H1 2026 results - Stock Titan
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
Adagene (NASDAQ:ADAG) CEO Peter Luo Acquires 22,966 Shares - MarketBeat
Exome Asset Management LLC Decreases Holdings in Adagene Inc. Sponsored ADR $ADAG - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Guggenheim reiterates Adagene stock Buy rating on competitor shift - Investing.com
Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary - Quartr
Adagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026 - The Globe and Mail
Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K - Stock Titan
ADAG - Finviz
Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG) - TradingView
Adagene (ADAG) upgraded to buy: Here's what you should know - MSN
Adagene (NASDAQ: ADAG) Schedule 13D/A details Luo group and trust stakes - Stock Titan
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Are medical stocks lagging Adagene (ADAG) this year? - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer - MSN
Adagene Inc. (ADAG) Presses Lower: Support Test in Sight After 1.88% DeclineTriple EMA - dars.gov.et
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - sharewise.com
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Adagene to Participate in Two Upcoming Investor Conferences - marketscreener.com
Janus Henderson (ADAG) reports 6.67M ADRs, 10.1% stake (04/30/2026) - Stock Titan
Adagene Inc Adr Stock (ADAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):